FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:1412-1413 May 2, 2002 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Csernansky et al. (Jan. 3 issue)¹ found that adult outpatients with clinically stable schizophrenia or schizoaffective disorder had a lower risk of relapse if they were treated with risperidone than if they were treated with haloperidol. The rate of dropout because of adverse events or poor compliance, or for other reasons, was 50 percent higher in the haloperidol group. Risperidone was better tolerated than haloperidol, which is a known advantage of atypical antipsychotic drugs. The haloperidol group received a relatively high mean modal dose (11.7 mg per day). The greater frequency of side effects may have led . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.